NCI and the STELLAR trial.
The Lancet
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000191:economics*; D005260:Female; D006801:Humans; D000077289:Letrozole; D009316:National Institutes of Health (U.S.) / Q000191:economics; D009570:Nitriles / Q000627:therapeutic use*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D014481:United States
D000970:Antineoplastic Agents; D009570:Nitriles; D020845:Selective Estrogen Receptor Modulators; D014230:Triazoles; D020849:Raloxifene Hydrochloride; D000077289:Letrozole